Next Article in Journal
At the Heart of It All: Emotions of Consequence for the Conceptualization of Caregiver-Reported Outcomes in the Context of Colorectal Cancer
Next Article in Special Issue
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise
Previous Article in Journal
Single-Center Comparison of [64Cu]-DOTAGA-PSMA and [18F]-PSMA PET–CT for Imaging Prostate Cancer
Previous Article in Special Issue
Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 28
Issue 5
10.3390/curroncol28050354
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group

by
Wei Fang Dai
1,2,†,
Vanessa Arciero
1,†,
Erica Craig
3,
Brent Fraser
4,
Jessica Arias
5,
Darryl Boehm
6,
Nevzeta Bosnic
7,
Patricia Caetano
8,
Carole Chambers
9,
Barry Jones
10,
Elena Lungu
7,
Gunita Mitera
11,
Tanya Potashnik
7,
Anthony Reiman
12,13,14,
Trevor Ritcher
4,
Jaclyn M. Beca
2,5,
Avram Denburg
15,
Rebecca E. Mercer
2,5,
Ambica Parmar
16,
Mina Tadrous
17,
Pam Takhar
5,
Kelvin K. W. Chan
1,2,16,* and
on behalf of the CanREValue Collaboration Reassessment and Uptake Working Group
‡add Show full author list remove Hide full author list
1
Temerty Faculty of Medicine, University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada
2
Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada
3
New Brunswick Cancer Network, Saint John, NB E2J 3S4, Canada
4
Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada
5
Ontario Health (CCO), Toronto, ON M5G 2L7, Canada
6
Saskatchewan Cancer Agency, Regina, SK S4W 0G3, Canada
7
Patented Medicine Prices Review Board, Ottawa, ON K1P 1C1, Canada
8
Government of Manitoba, Winnipeg, MB R3B 3M9, Canada
9
Alberta Health Services, Edmonton, AB T5J 3E4, Canada
10
Health Canada, Ottawa, ON K1Y 4X2, Canada
11
Canadian Association of Provincial Cancer Agencies, Toronto, ON M5H 1J9, Canada
12
Department of Medicine, Dalhousie University, Halifax, NS B3H 2Y9, Canada
13
Department of Biology, University of New Brunswick, Fredericton, NB E3B 5A3, Canada
14
Department of Oncology, Saint John Regional Hospital, Saint John, NB E2L 42L, Canada
15
The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
16
Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
17
Women’s College Hospital, Toronto, ON M5S 1B2, Canada
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
†
Wei Fang Dai and Vanessa Arciero contributed equally to this work.
‡
Membership of the CanREValue Collaboration Reassessment and Uptake Working Group is provided in the Acknowledgments.
Curr. Oncol. 2021, 28(5), 4174-4183; https://doi.org/10.3390/curroncol28050354
Submission received: 28 August 2021 / Revised: 4 October 2021 / Accepted: 4 October 2021 / Published: 16 October 2021
(This article belongs to the Special Issue Access to Cancer Drugs in Canada)
Review Reports Versions Notes

Abstract

The Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) Collaboration was established to develop a framework for generating and using real-world evidence (RWE) to inform the reassessment of cancer drugs following initial health technology assessment (HTA). The Reassessment and Uptake Working Group (RWG) is one of the five established CanREValue Working Groups. The RWG aims to develop considerations for incorporating RWE for HTA reassessment and strategies for using RWE to reassess drug funding decisions. Between February 2018 and December 2019, the RWG attended four teleconferences (with follow-up surveys) and two in-person meetings to discuss recommendations for the development of a reassessment process and potential barriers and facilitators. Modified Delphi methods were used to gather input. A draft report of recommendations (to December 2018) was shared for public consultation (December 2019 to January 2020). Initial considerations for developing a reassessment process were proposed. Specifically, reassessment can be initiated by diverse stakeholders, including decision makers from public drug plans or industry stakeholders. The reassessment process should be modelled after existing deliberation and recommendation frameworks used by HTA agencies. Proposed reassessment outcome categories include maintaining status quo, revisiting funding criteria, renegotiating price, or disinvesting. Overall, these initial considerations will serve as the basis for future advancements by the Collaboration.
Keywords: health technology assessment; real-world evidence; reassessment health technology assessment; real-world evidence; reassessment

Share and Cite

MDPI and ACS Style

Dai, W.F.; Arciero, V.; Craig, E.; Fraser, B.; Arias, J.; Boehm, D.; Bosnic, N.; Caetano, P.; Chambers, C.; Jones, B.; et al. Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group. Curr. Oncol. 2021, 28, 4174-4183. https://doi.org/10.3390/curroncol28050354

AMA Style

Dai WF, Arciero V, Craig E, Fraser B, Arias J, Boehm D, Bosnic N, Caetano P, Chambers C, Jones B, et al. Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group. Current Oncology. 2021; 28(5):4174-4183. https://doi.org/10.3390/curroncol28050354

Chicago/Turabian Style

Dai, Wei Fang, Vanessa Arciero, Erica Craig, Brent Fraser, Jessica Arias, Darryl Boehm, Nevzeta Bosnic, Patricia Caetano, Carole Chambers, Barry Jones, and et al. 2021. "Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group" Current Oncology 28, no. 5: 4174-4183. https://doi.org/10.3390/curroncol28050354

APA Style

Dai, W. F., Arciero, V., Craig, E., Fraser, B., Arias, J., Boehm, D., Bosnic, N., Caetano, P., Chambers, C., Jones, B., Lungu, E., Mitera, G., Potashnik, T., Reiman, A., Ritcher, T., Beca, J. M., Denburg, A., Mercer, R. E., Parmar, A., ... on behalf of the CanREValue Collaboration Reassessment and Uptake Working Group. (2021). Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group. Current Oncology, 28(5), 4174-4183. https://doi.org/10.3390/curroncol28050354

Article Metrics

Back to TopTop